Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

Trial Details

NCT ID

NCT05979818

Phase

PHASE1

Sponsor

Second Xiangya Hospital of Central South University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Propranolol hydrochloride
• Sintilimab
• Chemotherapy

Locations (sample)

• Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

• Sign a written informed consent prior to any research-related procedure
• Age ≥18 years and ≤ 75 years old
• ECOG PS score of 0-1
• Expected survival time ≥ 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →